Arcutis’s Phase III AD Win Bodes Well For Soon-To-Report Second Study

One analyst said efficacy data for roflumilast in INTEGUMENT-1 suggest limited competitiveness against Incyte’s topical JAK inhibitor, Opzelura, while others were more optimistic.

Arcutis announced Phase III results for roflumilast in atopic dermatitis • Source: Shutterstock

Arcutis Biotherapeutics, Inc.’s Phase III study for roflumilast cream in mild-to-moderate atopic dermatitis (AD) hit its primary endpoint, raising hopes of a second Phase III win before the year is up and, with that, boosting chances for US Food and Drug Administration approval. But how roflumilast will fare in a crowded market for topical AD treatments – especially against existing players like Incyte Corporation’s Opzelura (ruxolitinib) and Pfizer Inc.’s Eucrisa (crisaborole) – remains to be seen.

Arcutis announced positive topline results from the pivotal INTEGUMENT-1 trial of roflumilast cream 0.15% on 15 November. The drug is...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D